A randomized controlled trial of mirabegran and fesoterodine in overactive bladder

A randomized controlled trial of mirabegran and fesoterodine in overactive bladder - A randomized controlled trial of mirabegran and fesoterodine in overactive bladder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038196

Enrollment

150

Registered

2020-03-01

Start date

2020-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

overactive bladder

Interventions

the intervention of fesoterodine as the treatment of overactive bladder the intervention of mirabegron as the treatment of overactive bladder

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: total score of overactive bladder symptom score >3, score of question 3 in overactive bladder symptom score >2

Exclusion criteria

Exclusion criteria: patients with a history of hypersensitivity to fesoterodine or mirabegron

Design outcomes

Primary

Measure	Time frame
total score of overactive bladder symptom score	—

Secondary

Measure	Time frame
each score of overactive bladder symptom score, total score of overactive bladder symptom score international prostate symptom score, total score of King's Health Questionnaire, frequency volume chart, urofluometry, residual urine	—

Countries

Japan

Contacts

Public ContactTomohiko Kamasako

Dokkyo Medical University Hospital Department of Urology, Continence Center

kamasako@dokkyomed.ac.jp0282861111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026